Is There a Common Resilience Mechanism Underlying Antidepressant Drug Response? Evidence From 2848 Patients
J Clin Psychiatry 2007;68(8):1195-1205
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objectives: Timing issues of antidepressant drug response are of major clinical relevance, given our current inability to predict when a particular patient will respond to a particular treatment.
Method: We detailed the time characteristics of recovery in a study of 2848 patients (diagnosed according to DSM-III-R/DSM-IV criteria as having major depressive disorder or major depressive episode) who were treated with 7 different antidepressants and placebo. A 2-dimensional cure model was used to disentangle the 2 central aspects of psychotropic drug response: the proportion of patients in whom a therapeutic response is induced (incidence) and the time to onset of improvement (latency). Random-effects models were applied to quantify unexplained heterogeneity. Patients were recruited between June 1982 and May 1998.
Results: Our analyses yielded no indication for a delayed onset of antidepressant drug response. Rather, we found highly individual time characteristics of recovery along with a continuous distribution of the time spans to onset of improvement under treatment with all active compounds and placebo. The mean ± SD time to onset of improvement was 13 ± 1 days and to response was 19 ± 1 days. Effective antidepressants appeared to trigger and maintain conditions necessary for recovery from the disorder. Odds-ratio analysis based on a random-effects model revealed that early improvers were at least 3 times more likely to become sustained responders with a pooled OR of 9.25, 95% CI = 7.79 to 10.98.
Conclusions: Affectively ill patients are likely to possess a common, biological, "resilience"-like component that largely controls recovery from depression. Once triggered, recovery appears to follow a pattern similar to the course observed with placebo, despite marked pharmacologic differences of the triggers. These findings may pave the way for new classes of psychotropic drugs specifically designed to support health-oriented processes underlying the natural resilience of patients.